Patents by Inventor Douglas W. Schneider

Douglas W. Schneider has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Factor VIII Variants and Methods of Use
    Publication number: 20120142593
    Abstract: A Factor VIII fusion protein or a Factor VIII fusion heterodimer comprising Factor VIII in which an amino acid sequence of a modulator is present in the B-domain, or an amino acid sequence of a modulator replaces some or all of the amino acid sequence of the B-domain is disclosed. Nucleic acids encoding the inventive fusion proteins and fusion heterodimers are also disclosed, as are methods for producing the fusion proteins and fusion heterodimers, pharmaceutical compositions, and methods of treating deficiencies in coagulation with the inventive fusion molecules.
    Type: Application
    Filed: March 24, 2010
    Publication date: June 7, 2012
    Applicant: BAYER HEALTHCARE LLC
    Inventors: Xiao-Yan Zhao, Peter John Kretschmer, Thomas Eugene Thompson, Douglas W. Schneider, John Edward Murphy
  • Isolated human antibodies that bind epitopes on RG1
    Patent number: 7893217
    Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to antibodies directed against the polypeptides and to methods for using the polynucleotides, and polypeptides, and antibodies in research, diagnosis, and therapeutic applications.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: February 22, 2011
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas W. Schneider
  • Methods for treating disease-states associated with RG1 using immunoconjugates
    Patent number: 7887804
    Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to antibodies directed against the polypeptides and to methods for using the polynucleotides, and polypeptides, and antibodies in research, diagnosis, and therapeutic applications.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: February 15, 2011
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas W. Schneider
  • DNA encoding a novel RG1 polypeptide
    Publication number: 20090292112
    Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to antibodies directed against the polypeptides and to methods for using the polynucleotides, and polypeptides, and antibodies in research, diagnosis, and therapeutic applications.
    Type: Application
    Filed: October 30, 2007
    Publication date: November 26, 2009
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas W. Schneider
  • DNA encoding a novel RG1 polypeptide
    Publication number: 20090214422
    Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to antibodies directed against the polypeptides and to methods for using the polynucleotides, and polypeptides, and antibodies in research, diagnosis, and therapeutic applications.
    Type: Application
    Filed: October 30, 2007
    Publication date: August 27, 2009
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas W. Schneider
  • DNA encoding a novel RG1 polypeptide
    Publication number: 20040152139
    Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to antibodies directed against the polypeptides and to methods for using the polynucleotides, and polypeptides, and antibodies in research, diagnosis, and therapeutic applications.
    Type: Application
    Filed: July 22, 2003
    Publication date: August 5, 2004
    Applicant: Schering Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas W. Schneider
  • DNA encoding a novel RG1 polypeptide
    Publication number: 20040023307
    Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to methods for utilizing the polynucleotides and polypeptides in research, diagnosis, and therapeutic applications.
    Type: Application
    Filed: July 8, 2003
    Publication date: February 5, 2004
    Applicant: Schering Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Douglas W. Schneider, Renate Parry
  • DNA encoding a novel RG1 polypeptide
    Patent number: 6682902
    Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to methods for utilizing the polynucleotides and polypeptides in research, diagnosis, and therapeutic applications.
    Type: Grant
    Filed: December 7, 2000
    Date of Patent: January 27, 2004
    Assignee: Schering Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Douglas W. Schneider, Renate Steinbrecher
  • DNA encoding a novel PROST 03 polypeptide
    Publication number: 20020009455
    Abstract: The present invention relates to novel human polypeptides, designated PROST 03, which exhibit an expression pattern showing a high specificity toward prostate tissues, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to methods for utilizing the polynucleotides and polypeptides in research, diagnosis, and therapeutic applications.
    Type: Application
    Filed: April 20, 2001
    Publication date: January 24, 2002
    Inventors: Ted Lau, Richard J. Lin, Deborah Parkes, Gordon Parry, Douglas W. Schneider, Renate Steinbrecher, Pamela Toy Van Heuit, John Wu
  • DNA encoding a novel RG1 polypeptide
    Publication number: 20020004047
    Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to methods for utilizing the polynucleotides and polypeptides in research, diagnosis, and therapeutic applications.
    Type: Application
    Filed: December 7, 2000
    Publication date: January 10, 2002
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Douglas W. Schneider, Renate Steinbrecher
  • Epidermal growth factor receptor antibodies
    Patent number: 6129915
    Abstract: The present invention is related to single and double chain antibodies to EGF receptor. The invention also relates to toxin conjugates of such antibodies. These antibodies are useful for treating and diagnosing the status of pathological conditions such as cancer and cellular hyper proliferation.
    Type: Grant
    Filed: April 23, 1999
    Date of Patent: October 10, 2000
    Assignee: Schering Aktiengesellschaft
    Inventors: Winfried S. Wels, Mathias Schmidt, Evangelia Vakalopoulou, Douglas W. Schneider
  • Growth factor receptor antibodies
    Patent number: 5942602
    Abstract: The present invention is related to single and double chain antibodies to EGF receptor. The invention also relates to toxin conjugates of such antibodies. These antibodies are useful for treating and diagnosing the status of pathological conditions such as cancer and cellular hyper proliferation.
    Type: Grant
    Filed: February 13, 1997
    Date of Patent: August 24, 1999
    Assignee: Schering Aktiengessellschaft
    Inventors: Winfried S. Wels, Mathias Schmidt, Evangelia Vakalopoulou, Douglas W Schneider